Document Detail


Drug-eluting stent fracture: incidence, contributing factors, and clinical implications.
MedLine Citation:
PMID:  20025045     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Stent fracture has been observed in noncoronary vessels, especially in the superficial femoral and popliteal arteries and with bare metal stents in saphenous vein grafts of coronary arteries. Since the introduction of drug-eluting stents, stent fractures have also been reported in small studies and case reports. We reviewed these publications to assess what is known regarding the incidence, contributing factors, and clinical implications of drug-eluting stent fracture in coronary arteries. The reported rate of drug-eluting stent fracture in coronary arteries ranges from 1 to 8%, although much of the available literature is derived from single-center studies that are heterogeneous in their study methods. A higher risk of stent fracture may be associated with the right coronary artery location, excessive tortuosity or angulation of the vessel, overlapping stents, and longer stents. The closed-cell design of the Cypher stent has been associated with increased rigidity that may increase the risk of stent fracture, although these studies did not assess the overall outcomes between the Cypher and Taxus stents in a head-to-head comparison. Stent fracture has been shown by most studies to be associated with a statistically increased incidence of focal in-stent restenosis, and some have shown an increased risk of target lesion revascularization. Other complications observed with stent fracture include stent thrombosis, coronary aneurysms, myocardial infarction, and sudden death.
Authors:
Timothy Canan; Michael S Lee
Related Documents :
10936135 - Efficacy and tolerance of a new silicone stent for the treatment of benign tracheal ste...
20678385 - Stenting for extracranial stenotic lesions of carotid and vertebral arteries.
15071775 - Endograft use in the femoral and popliteal arteries.
7529445 - A new self-expansive intraurethral stent using shape memory alloy: a preliminary report...
4059065 - "absent" pulmonary valve with atrial septal defect and patent ductus arteriosus.
15818305 - Cd8 t lymphocytes do not express cytotoxic proteins in coronary artery aneurysms in acu...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions     Volume:  75     ISSN:  1522-726X     ISO Abbreviation:  Catheter Cardiovasc Interv     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-01-27     Completed Date:  2010-04-01     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100884139     Medline TA:  Catheter Cardiovasc Interv     Country:  United States    
Other Details:
Languages:  eng     Pagination:  237-45     Citation Subset:  IM    
Affiliation:
Division of Cardiology, David Geffen School of Medicine at University of California, Los Angeles, California, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Angioplasty, Transluminal, Percutaneous Coronary / adverse effects,  instrumentation*
Cardiovascular Agents / administration & dosage*
Coronary Angiography
Coronary Artery Disease / radiography,  therapy*,  ultrasonography
Drug-Eluting Stents*
Equipment Failure Analysis
Female
Humans
Male
Middle Aged
Paclitaxel / administration & dosage*
Prosthesis Design
Prosthesis Failure*
Risk Assessment
Risk Factors
Sirolimus / administration & dosage*
Time Factors
Treatment Outcome
Ultrasonography, Interventional
Chemical
Reg. No./Substance:
0/Cardiovascular Agents; 33069-62-4/Paclitaxel; 53123-88-9/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Insular thyroid carcinoma in a patient with Cowden syndrome.
Next Document:  Developmental and reproductive toxicology studies in nonhuman primates.